550 related articles for article (PubMed ID: 15870208)
1. Molecular dynamics and protein function.
Karplus M; Kuriyan J
Proc Natl Acad Sci U S A; 2005 May; 102(19):6679-85. PubMed ID: 15870208
[TBL] [Abstract][Full Text] [Related]
2. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.
Lin YL; Roux B
J Am Chem Soc; 2013 Oct; 135(39):14741-53. PubMed ID: 24001034
[TBL] [Abstract][Full Text] [Related]
3. A Src-like inactive conformation in the abl tyrosine kinase domain.
Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
[TBL] [Abstract][Full Text] [Related]
4. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
[TBL] [Abstract][Full Text] [Related]
5. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Seeliger MA; Ranjitkar P; Kasap C; Shan Y; Shaw DE; Shah NP; Kuriyan J; Maly DJ
Cancer Res; 2009 Mar; 69(6):2384-92. PubMed ID: 19276351
[TBL] [Abstract][Full Text] [Related]
6. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.
Hari SB; Perera BG; Ranjitkar P; Seeliger MA; Maly DJ
ACS Chem Biol; 2013 Dec; 8(12):2734-43. PubMed ID: 24106839
[TBL] [Abstract][Full Text] [Related]
7. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Lin YL; Meng Y; Jiang W; Roux B
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
[TBL] [Abstract][Full Text] [Related]
8. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
Nagar B
J Nutr; 2007 Jun; 137(6 Suppl 1):1518S-1523S; discussion 1548S. PubMed ID: 17513418
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
[TBL] [Abstract][Full Text] [Related]
10. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
11. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Schindler T; Bornmann W; Pellicena P; Miller WT; Clarkson B; Kuriyan J
Science; 2000 Sep; 289(5486):1938-42. PubMed ID: 10988075
[TBL] [Abstract][Full Text] [Related]
12. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Pricl S; Fermeglia M; Ferrone M; Tamborini E
Mol Cancer Ther; 2005 Aug; 4(8):1167-74. PubMed ID: 16093432
[TBL] [Abstract][Full Text] [Related]
13. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Lee TS; Ma W; Zhang X; Giles F; Cortes J; Kantarjian H; Albitar M
Mol Cancer Ther; 2008 Dec; 7(12):3834-41. PubMed ID: 19056677
[TBL] [Abstract][Full Text] [Related]
15. Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations.
Pereira EG; Moreira MA; Caffarena ER
J Mol Model; 2012 Sep; 18(9):4333-41. PubMed ID: 22570081
[TBL] [Abstract][Full Text] [Related]
16. Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
Dixit A; Verkhivker GM
PLoS Comput Biol; 2009 Aug; 5(8):e1000487. PubMed ID: 19714203
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine kinases: autoregulation and small-molecule inhibition.
Hubbard SR
Curr Opin Struct Biol; 2002 Dec; 12(6):735-41. PubMed ID: 12504677
[TBL] [Abstract][Full Text] [Related]
18. Study of the interaction surface for the c-Src-imatinib complex by a molecular dicing technique.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(3):436-7. PubMed ID: 18159983
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Lee TS; Potts SJ; Kantarjian H; Cortes J; Giles F; Albitar M
Cancer; 2008 Apr; 112(8):1744-53. PubMed ID: 18338744
[TBL] [Abstract][Full Text] [Related]
20. Conformational disturbance in Abl kinase upon mutation and deregulation.
Iacob RE; Pene-Dumitrescu T; Zhang J; Gray NS; Smithgall TE; Engen JR
Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1386-91. PubMed ID: 19164531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
